Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.54 |
| ▸ | TUBB | P07437 | 1/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.54 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386796 | 0.87 | STAT3 (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30832961 | 0.87 | STAT3 (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4388703 | 0.84 | PKM (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4388147 | 0.84 | GFER (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4438683 | 0.81 | CYP2C9 (0.69) | HPGDCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL737610 | 0.79 | GFER (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27710581 | 0.79 | MAPT (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4389790 | 0.78 | CYP1A2 (0.67) | GFERHPGDCYP2C19ALDH1A1KDM4E | |
| SCHEMBL4396076 | 0.78 | CYP1A2 (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Indole-3-Acetic Acid SCHEMBL26344 | 0.78 | MEN1 (0.75) | HPGDCYP2C9CYP2C19ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893575-B1 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H LUNDBECK AS (DK) | 2017-01-11 | — | — | EP | disclosed |
| US-7629473-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2009-12-08 | — | — | US | disclosed |
| CN-101238101-A | 2-(1H-indolylsulfanyl)-aryl amine derivatives | LUNDBECK & CO AS H (DK) | 2008-08-06 | — | — | CN | disclosed |
| EP-1893575-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H.Lundbeck A/S (DK) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134499-A2 | 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | WO | disclosed |
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | H. LUNDBECK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287382-A1 | 2-(1H-indolylsulfanyl)-aryl amine derivatives | CYP11B2, CYP1A2, CYP4B1 | TUBB4A 86/4885TUBB 215/4885TUBA3C 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.